title: Extracellular signal-regulated kinases (ERKs) modulate cocaine-induced gene expression in the mouse amygdala.
abstract: It is known that acute cocaine administration activates the extracellular signal-regulated kinase (ERK) pathway in the striatum, and results in transcription and translation of immediate early genes (IEGs). In the present study we investigated a possible involvement of ERK in the regulation of IEG expression in the amygdala, another brain structure known to be related to an addicted state. The patterns of cocaine-induced c-Fos, JunB and Zif268 protein expression were investigated, using an immunohistochemical approach, within distinct nuclei of the amygdala, either in the presence or absence of a selective inhibitor of the ERK pathway, SL327. Although these IEGs were similarly activated in the various nuclei of the amygdala after acute administration of cocaine, they showed different patterns after chronic injections. They also showed selective sensitivities to ERK inhibition. In particular, whereas c-Fos and JunB expressions were augmented following chronic cocaine treatment, as compared with acute treatment, Zif268 expression was decreased by this chronic treatment. Additionally, chronic blocking of ERK activation affected cocaine-induced c-Fos and JunB but not Zif268 expression. Thus, the differential involvement of ERK in chronic vs. acute regulation of IEGs may account for its specific role in addiction-related behavioral alterations, such as sensitization and tolerance.
authors.affiliation: Laboratory of Molecular Neurobiology, Nencki Insitute, Pasteura 3, 02 093 Warsaw, Poland.
authors.forename: Kasia
authors.initials: K
authors.lastname: Radwanska
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Caboche
authors.forename: Leszek
authors.initials: L
authors.lastname: Kaczmarek
mesh_terms: D000607:Aminoacetonitrile / Q000031:analogs & derivatives; D000679:Amygdala / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage*; D004268:DNA-Binding Proteins / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D051766:Early Growth Response Protein 1; D048049:Extracellular Signal-Regulated MAP Kinases / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects*; D017874:Immediate-Early Proteins / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D051379:Mice; D011480:Protease Inhibitors / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D018765:Dopamine Uptake Inhibitors; D051766:Early Growth Response Protein 1; C486109:Egr1 protein, mouse; D017874:Immediate-Early Proteins; D011480:Protease Inhibitors; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; C424127:SL 327; D014157:Transcription Factors; D000607:Aminoacetonitrile; D048049:Extracellular Signal-Regulated MAP Kinases; D003042:Cocaine